FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

RFK Jr. Tones Down Vaccine Skepticism in Run Up to Midterms

[ Price : $8.95]

HHS secretary Robert F. Kennedy Jr. curtails his public commentary on vaccines as part of a deliberate political strategy by the T...

Alymsys Patient Brochure False or Misleading: FDA

[ Price : $8.95]

The CDER Office of Prescription Drug Promotion says an Amneal patient brochure for its Avastin biosimilar Alymsys is false or misl...

America First Fee Incentives Discussed in PDUFA Meeting

[ Price : $8.95]

Minutes of the 3/10 and 3/12 PDUFA 8 reauthorization steering committee sessions, progress was reported on the America First fee i...

Granules Steps Up Oversight at Troubled India Facility

[ Price : $8.95]

Granules India Ltd tightens oversight of its manufacturing operations at its largest facility based on FDA-documented compliance i...

Inspection Cites Thermo Fisher Manufacturing Facility

[ Price : $8.95]

FDA cites GMP deficiencies at a facility operated by Thermo Fisher Scientific (Patheon Italia unit) in Ferentino, Italy.

FDA Budget Proposal Signals Push for Tighter Ad Oversight

[ Price : $8.95]

Law firm Sheppard breaks down some of FDAs proposals in its budget documents that industry should keep a close eye on, including n...

Workshop on Novel Surrogate Endpoints for Rare Disease Drugs

[ Price : $8.95]

FDA announces a 5/18 virtual public workshop aimed at advancing the use of novel surrogate endpoints in developing treatments for ...

Insmed Halts Brensocatib Program After Mid-Stage Trial Miss

[ Price : $8.95]

Insmed discontinues development of its drug candidate brensocatib for hidradenitis suppurativa after a mid-stage clinical trial fa...

See Supply Chain Strategy as Core Regulatory Function: Attorney

[ Price : $8.95]

Baker Hostetler attorney Winston Kirton says life sciences companies that are active in both the U.S. and the EU need to change th...

FDA Not Keeping Pace with Non-Oncology Basket Trials: Column

[ Price : $8.95]

A Clinical Trial Vanguard online column explains how a 2022 FDA master protocol guidance has not kept pace with non-oncology baske...